a-LOW-se-tron
Therapeutic Classification: anti irritable bowel syndrome agents
Pharmacologic Classification: five ht3 antagonists
REMS
Severe diarrhea-predominant irritable bowel syndrome (IBS) in women who have chronic symptoms (≥6 mo), no other GI pathology, and have had no response to conventional therapy.
Absorption: 50–60% absorbed following oral administration.
Distribution: Widely distributed to tissues.
Half-Life: 1.5 hr.
(pain/discomfort, diarrhea)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO | within 1–2 wk | up to 6 wk | 1 wk‡ |
‡Following discontinuation.
Contraindicated in:
Use Cautiously in:
GI: constipation
Drug-drug:
Monitor patient for signs of constipation or ischemic colitis (new or worsening abdominal pain, bloody diarrhea, blood in stool) during therapy. Patients should not start taking alosetron if they are constipated. Discontinue therapy immediately if patient develops constipation or signs/symptoms of ischemic colitis.
Caution patient to stop taking alosetron and report constipation or signs of ischemic colitis to health care professional immediately. Immediately contact health care professional again if constipation does not resolve after discontinuation of alosetron. Alosetron should be resumed only after constipation has resolved and on the advice of their health care professional. Treatment with alosetron should not be resumed in patients who develop ischemic colitis.
NDC Code